Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Sinclair

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
World Journal of Hepatology|November 17, 2021
Clinical outcomes of patients with two small hepatocellular carcinomasAnh Duy Pham, Karl Vaz, Zaid S Ardalan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC studyWilliam Kemp, Ammar Majeed, Joanne Mitchell, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Cancers|September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
World Journal of Hepatology|November 17, 2021
Clinical outcomes of patients with two small hepatocellular carcinomasAnh Duy Pham, Karl Vaz, Zaid S Ardalan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 15, 2021
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC studyWilliam Kemp, Ammar Majeed, Joanne Mitchell, et al.
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Cancers|December 23, 2023
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie Ngu, et al.
Cancers|June 19, 2024
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Cancers|September 14, 2024
Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort StudyJonathan Abdelmalak, Simone I Strasser, Natalie L Ngu, et al.
Pageof 10